Osteocalcin in congenital adrenal hyperplasia

Area of Science:

• Pediatric Endocrinology
• Bone Metabolism
• Steroid Hormone Therapy

Background:

• Glucocorticoid therapy is known to inhibit bone turnover.
• Congenital adrenal hyperplasia (CAH) requires long-term glucocorticoid and mineralocorticoid treatment.
• Osteocalcin is a key biomarker for bone turnover.

Purpose of the Study:

• To evaluate serum osteocalcin levels in children with CAH undergoing glucocorticoid and mineralocorticoid treatment.
• To assess the impact of 1,25(OH)2D3 (calcitriol) on bone turnover markers in these children.
• To investigate the relationship between hormone levels and bone health in pediatric CAH.

Main Methods:

• Study included 75 children (aged 1-18 years) with CAH on long-term substitution therapy.
• Serum levels of osteocalcin, alkaline phosphatase, calcium, phosphate, and 17-OH progesterone were measured.
• Bone mineral density was assessed to rule out osteoporosis.
• Intervention with 1,25(OH)2D3 was administered to a subset of patients.

Main Results:

• Children with CAH exhibited low serum osteocalcin and alkaline phosphatase levels.
• Calcium and phosphate levels remained within normal ranges.
• Despite biochemical abnormalities, no osteoporosis was detected, and normal growth was observed, potentially due to elevated androgens.
• Treatment with 1,25(OH)2D3 led to an increase in osteocalcin levels, followed by alkaline phosphatase and bone isoenzyme.
• Elevated 17-OH progesterone levels averaged 11.8 nmol/l.

Conclusions:

• Long-term glucocorticoid and mineralocorticoid therapy in children with CAH is associated with suppressed bone turnover markers.
• Elevated androgen levels may mitigate the negative effects on bone density and growth.
• 1,25(OH)2D3 supplementation shows promise in improving bone turnover markers in pediatric CAH.
• Further research is warranted to fully understand bone metabolism in CAH patients on long-term steroid therapy.